Phase 2 Stroke Trial, Recruiting NCT07283159 Sponsor: General Hospital of Shenyang Military Region Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT07283159
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) confirmed by a brain scan
  • People where the time since they were last known to be well is within 4.5 hours of treatment
  • People with a stroke severity score of 6 or higher at the time of enrolment (this score measures how much the stroke has affected the body and brain)
  • People who have received a clot-dissolving medication called tenecteplase (0.25mg/kg) by intravenous drip
  • People experiencing their first stroke, or who have had a previous stroke but recovered with little to no lasting disability
  • People who have given signed consent to participate

Who may not be able to join:

  • People who are planned to receive a procedure to remove or treat the clot directly inside a blood vessel (endovascular treatment)
  • People who have already received certain specific medications after this stroke episode began (Edaravone Injection, Edaravone Dexborneol Injection, Butylphthalide Injection, or Butylphthalide Capsules)
  • People who have taken a type of blood pressure medication called ACE inhibitors within a certain time period before the trial drug would be given (confirm with trial site for exact timeframe)
  • People who are pregnant
  • People who have a known allergy to the trial drug(s)
  • People who have other serious health conditions alongside their stroke
  • People who have participated in another clinical trial within the past 3 months
  • People the research team considers unsuitable for the study for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
General Hospital of Shenyang Military Region
Registry
ClinicalTrials.gov
Start date
20 January 2026
Est. completion
30 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

proportion of excellent functional outcome (modified Rankin Scale (mRS) 0-1)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov